Abstract: In China, the majority of biological products on the market and under new drug application are biosimilar ones, and there are no guidelines and technical requirements on clinical assessment for biosimilar products available now.We expect to obtain some useful information in this field in referring to the updated international guidelines.

Key words: biosimilar products, clinical evaluation